Subscribe to stay informed!
A West Chester pharmaceutical company finally achieved federal approval of a new drug candidate that treats a contagious skin disease, writes John George for the…
West Chester-based Verrica Pharmaceuticals is expecting to raise $32.5 million from the sale of 750,000 shares of its common stock at $6…
West Chester’s Verrica Pharmaceuticals is seeking FDA approval to market the drug “Ycanth,” which treats a skin condition, writes John George for the Philadelphia…
West Chester-based Verrica Pharmaceuticals has received a trigger payment of $8 million from its product development partner in Japan after a provision from their…
West Chester-based Verrica Pharmaceuticals has moved closer to getting a second chance at approval for its skin disorder drug, writes John George for the…
At the start of the week, the stock market entered bear territory for the first time since 2020, further pushing down many local companies that…
West Chester-based Verrica Pharmaceuticals is looking to raise around $30 million from its public stock offering, writes John George for The Philadelphia Business Journal…
West Chester-based Verrica Pharmaceuticals saw its stock plunge by nearly 22 percent after the FDA voiced concerns about its lead drug candidate, VP-102…
Verrica Pharmaceuticals in West Chester is seeking approval from the Food and Drug Administration for a new drug to treat molluscum contagiosum, a common and…
Verrica Pharmaceuticals, a dermatology company based in West Chester, is planning to go public with an initial public stock offering of $75 million, writes John…
Before we send you to this site, please subscribe to our daily newsletter.